Table 1.

Study year	No. participating hospitals†	% C. glabrata of all Candida BSI isolates	No. BSI isolates of C. glabrata tested	No. (%) C. glabrata BSI isolates‡
Study year	No. participating hospitals†	% C. glabrata of all Candida BSI isolates	No. BSI isolates of C. glabrata tested	Fluconazole resistance	Echinocandin resistance§	Multidrug resistance¶
2008	13	11.7	68	0	0	0
2009	8	16.0	67	4 (6.0)	0	0
2010	8	16.8	60	4 (6.7)	0	0
2011	10	16.0	85	4 (4.7)	0	0
2012	11	17.0	108	3 (2.8)	0	0
2013	7	16.9	73	4 (5.5)	1 (1.4)	1 (1.4)
2014	7	22.1	123	11 (8.9)	0	0
2015	10	17.2	110	5 (4.5)	3 (2.7)	0
2016	10	21.2	123	4 (3.3)	4 (3.3)	2 (1.6)
2017	13	21.6	173	13 (7.5)	4 (2.3)	1 (0.6)
2018	13	23.9	168	14 (8.3)	4 (2.4)	2 (1.2)
Total	19	18.6	1158	66 (5.7)	16 (1.4)	6 (0.5)

Table 1. Incidence of antifungal resistance in Candida glabrata BSI isolates, based on cultures collected during a multicenter surveillance study, South Korea, 2008–2018*

*BSI, bloodstream infection.
†Hospitals participating in this laboratory-based nationwide multicenter surveillance system differed each year.
‡Antifungal susceptibility was determined by using the Clinical and Laboratory Standards Institute M27–4ED broth microdilution method^[16]. Interpretive categories of resistance were determined by using Clinical and Laboratory Standards Institute document M60-ED^[17]. We deposited 76 antifungal-resistant isolates of C. glabrata in the Korea Collection for Type Culture (KCTC; Jeongeup-si, Korea), including those showing resistance to fluconazole alone (60 isolates, KCTC nos. 37113–37172), echinocandin alone (10 isolates, KCTC nos. 37176–37185), and both fluconazole and echinocandin (6 multidrug-resistant isolates, KCTC nos. 37110–37112, 37173–37175). All 76 isolates were identified as C. glabrata by sequence analysis using the D1/D2 domain (GenBank accession nos. MW349716–90 and MW351777).
§Echinocandin resistance was confirmed by the identification of resistance hot-spot mutations in FKS1 and FKS2 in isolates that exhibited full or intermediate resistance to micafungin (MIC ≥0.12 mg/L) or caspofungin MIC (≥0.25 mg/L).
¶Multidrug resistance was defined as resistance to both fluconazole and echinocandins.

Table 2.

MLST genotype	Fluconazole susceptibility	No. isolates tested	No. with echinocandin resistance	No. isolates with 5 Pdr1p AAS found in both FR and F-SDD isolates					No. isolates with additional Pdr1p AAS except for 5 Pdr1p AAS
MLST genotype	Fluconazole susceptibility	No. isolates tested	No. with echinocandin resistance	P76S	P143T	D243N	E259G	T745A	1	2	Total
ST7	FR	37	6†						34	3	37
ST7	F-SDD	98	3						0		0
ST3	FR	7	0	7	7	7			6	1	7
ST3	F-SDD	43	1	43	43	43			0		0
ST26	FR	7	0						6		6
ST26	F-SDD	10	1						0		0
ST22	FR	1	0						1		1
ST22	F-SDD	16	1						0		0
ST10	FR	2	0						2		2
ST10	F-SDD	9	0						0		0
ST55	FR	2	0				2		2		2
ST55	F-SDD	6	1				6		1		1
ST2	FR	2	0						2		2
ST2	F-SDD	3	0						0		0
ST6	FR	1	0						1		1
ST6	F-SDD	5	2						0		0
ST59	FR	1	0					1	1		1
ST59	F-SDD	3	1					3	0		0
ST1	FR	2	0						2		2
ST12	F-SDD	2	0						0		0
Other STs‡	FR	4	0				1		2	2	4
Other STs‡	F-SDD	17	0	2	2	2			1		1
Total, no. (%)	FR	66	6	7	7	7	3	1	59	6§	65 (98.5)
Total, no. (%)	F-SDD	212	10	45	45	45	6	3	2¶		2 (0.9)

Table 2. Pdr1 AAS in 66 FR isolates and 212 F-SDD BSI isolates of Candida glabrata and their MLST genotypes, based on cultures collected during a multicenter surveillance study, South Korea, 2008–2018*

*AAS, amino acid substitution; BSI, bloodstream infection; FR, fluconazole-resistant; F-SDD, fluconazole-susceptible dose-dependent; MLST, multilocus sequence typing; ST, sequence type.
†All 6 isolates showed multidrug resistance, defined as resistance to both fluconazole and echinocandins.
‡Includes 21 STs that were each unique to a single isolate.
§Each of 6 FR isolates harbored 2 additional Pdr1 AAS (E340G/D919Y [ST7], Y556C/F580I [ST7], N132S/G1099S [ST7], F832L/L833V [ST3], G189V/E340G [other ST], and L366P/E555D [other ST]).
¶Two F-SDD isolates harbored additional Pdr1 AAS (V502I [ST55] and R250K [other ST]).

Table 3.

MLST genotype	No. isolates	Pdr1 AAS (no. isolates)†
MLST genotype	No. isolates	Inhibition domain	Fungal-specific transcription factor domain	Activation domain	Other regions
ST7	34	P327L (2), G334V (1), E340G (1), E340K (1), G346S (1), L347F (1), L375P (1), R376Q (1), S391L (1)	H576Y (2), G583C (1)	P927S (1), G943S (1), S947L (1), D954N (1), G1088E (1), Y1106N (1)	S236N (1), P258S (1), P258L (1), V260A (1),L280S (1), Y556C (1), E714D (1), T752I (1), N768D (1), R772K (1), K776E (1), G788W (2), L825P (1), T885A (1)
ST26	6	K365E (1), R376Q (1), F377I (1), E388Q (1)		N1091D (1)	S316I (1)
ST3	6	L347F (1)	Y584D (1)	T1080N (1), Y1106N (1)	A731E (1), N764D (1)
ST1	2		T607A (2)
ST2	2	G346S (2)
ST10	2	S337F (1), I392M (1)
ST55	2				F294S (1), P258S (1)
ST6	1			G1079R (1)
ST22	1			Y932C (1)
ST59	1	E369K (1)
Others	2		L935F (1)		P696L (1)
No. (%) isolates	59	20 (33.9)	7 (11.9)	11 (18.6)	21 (35.6)
No. (%) Pdr1 AAS	49	15 (30.6)	5 (10.2)	10 (20.4)	19 (38.8)

Table 3. Pdr1 AAS in 59 FR isolates of Candida glabrata BSI isolates and their MLST genotypes, based on cultures collected during a multicenter surveillance study, South Korea, 2008–2018*

*AAS, amino acid substitutions; BSI, bloodstream infection; FR, fluconazole-resistant; MLST, multilocus sequence typing; ST, sequence type.
†Previously reported Pdr1 AAS are shown in bold.

Arendrup MC. Epidemiology of invasive candidiasis. Curr Opin Crit Care. 2010;16:445–52.
Arendrup MC, Patterson TF. Multidrug-resistant Candida: epidemiology, molecular mechanisms, and treatment. J Infect Dis. 2017;216(suppl_3):S445–51.
Jensen RH, Johansen HK, Søes LM, Lemming LE, Rosenvinge FS, Nielsen L, et al. Posttreatment antifungal resistance among colonizing Candida isolates in candidemia patients: results from a systematic multicenter study. Antimicrob Agents Chemother. 2015;60:1500–8.
Pfaller MA, Diekema DJ, Turnidge JD, Castanheira M, Jones RN. Twenty years of the SENTRY antifungal surveillance program: results for Candida species from 1997–2016. Open Forum Infect Dis. 2019;6(Suppl 1):S79–94.
Chapman B, Slavin M, Marriott D, Halliday C, Kidd S, Arthur I, et al.; Australian and New Zealand Mycoses Interest Group. Changing epidemiology of candidaemia in Australia. J Antimicrob Chemother. 2017;72:1103–8.
Tan TY, Hsu LY, Alejandria MM, Chaiwarith R, Chinniah T, Chayakulkeeree M, et al. Antifungal susceptibility of invasive Candida bloodstream isolates from the Asia-Pacific region. Med Mycol. 2016;54:471–7.
Ferrari S, Ischer F, Calabrese D, Posteraro B, Sanguinetti M, Fadda G, et al. Gain of function mutations in CgPDR1 of Candida glabrata not only mediate antifungal resistance but also enhance virulence. PLoS Pathog. 2009;5: e1000268.
Tsai HF, Krol AA, Sarti KE, Bennett JE. Candida glabrata PDR1, a transcriptional regulator of a pleiotropic drug resistance network, mediates azole resistance in clinical isolates and petite mutants. Antimicrob Agents Chemother. 2006;50:1384–92.
Hull CM, Parker JE, Bader O, Weig M, Gross U, Warrilow AG, et al. Facultative sterol uptake in an ergosterol-deficient clinical isolate of Candida glabrata harboring a missense mutation in ERG11 and exhibiting cross-resistance to azoles and amphotericin B. Antimicrob Agents Chemother. 2012;56:4223–32.
Abbes S, Mary C, Sellami H, Michel-Nguyen A, Ayadi A, Ranque S. Interactions between copy number and expression level of genes involved in fluconazole resistance in Candida glabrata. Front Cell Infect Microbiol. 2013;3:74.
Vu BG, Moye-Rowley WS. Construction and use of a recyclable marker to examine the role of major facilitator superfamily protein members in Candida glabrata drug resistance phenotypes. MSphere. 2018;3:e00099–18.
Ferrari S, Sanguinetti M, Torelli R, Posteraro B, Sanglard D. Contribution of CgPDR1-regulated genes in enhanced virulence of azole-resistant Candida glabrata. PLoS One. 2011;6: e17589.
Hou X, Xiao M, Wang H, Yu SY, Zhang G, Zhao Y, et al. Profiling of PDR1 and MSH2 in Candida glabrata bloodstream isolates from a multicenter study in China. Antimicrob Agents Chemother. 2018;62:e00153–18.
Arastehfar A, Daneshnia F, Zomorodian K, Najafzadeh MJ, Khodavaisy S, Zarrinfar H, et al. Low level of antifungal resistance in Iranian isolates of Candida glabrata recovered from blood samples in a multicenter study from 2015 to 2018 and potential prognostic values of genotyping and sequencing of PDR1. Antimicrob Agents Chemother. 2019;63:e02503–18.
Hou X, Xiao M, Chen SC, Wang H, Yu SY, Fan X, et al. Identification and antifungal susceptibility profiles of Candida nivariensis and Candida bracarensis in a multi-center Chinese collection of yeasts. Front Microbiol. 2017;8:5.
Clinical and Laboratory Standards Institute. M27 reference method for broth dilution antifungal susceptibility testing of yeasts. 4th ed. Wayne (PA): Clinical and Laboratory Standards Institute; 2017.
Clinical and Laboratory Standards Institute. Performance standards for antifungal susceptibility testing of Yeasts. 1st ed. CLSI supplement M60. Wayne (PA): Clinical and Laboratory Standards Institute; 2017.
Clinical and Laboratory Standards Institute. Epidemiological cutoff values for antifungal susceptibility testing. 2nd ed. CLSI supplement M59. Wayne (PA): Clinical and Laboratory Standards Institute; 2018.
Rivero-Menendez O, Navarro-Rodriguez P, Bernal-Martinez L, Martin-Cano G, Lopez-Perez L, Sanchez-Romero I, et al. Clinical and laboratory development of echinocandin resistance in Candida glabrata: molecular characterization. Front Microbiol. 2019;10:1585.
Pappas PG, Kauffman CA, Andes DR, Clancy CJ, Marr KA, Ostrosky-Zeichner L, et al. Executive summary: clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;62:409–17.
Byun SA, Won EJ, Kim MN, Lee WG, Lee K, Lee HS, et al. Multilocus sequence typing (MLST) genotypes of Candida glabrata bloodstream isolates in Korea: association with antifungal resistance, mutations in mismatch repair gene (Msh2), and clinical outcomes. Front Microbiol. 2018;9:1523.
Kim MN, Shin JH, Sung H, Lee K, Kim EC, Ryoo N, et al. Candida haemulonii and closely related species at 5 university hospitals in Korea: identification, antifungal susceptibility, and clinical features. Clin Infect Dis. 2009;48:e57–61.
De Rosa FG, Trecarichi EM, Montrucchio C, Losito AR, Raviolo S, Posteraro B, et al. Mortality in patients with early- or late-onset candidaemia. J Antimicrob Chemother. 2013;68:927–35.
Nguyen MH, Clancy CJ, Yu VL, Yu YC, Morris AJ, Snydman DR, et al. Do in vitro susceptibility data predict the microbiologic response to amphotericin B? Results of a prospective study of patients with Candida fungemia. J Infect Dis. 1998;177:425–30.
Healey KR, Zhao Y, Perez WB, Lockhart SR, Sobel JD, Farmakiotis D, et al. Prevalent mutator genotype identified in fungal pathogen Candida glabrata promotes multi-drug resistance. Nat Commun. 2016;7:11128.
Niimi M, Nagai Y, Niimi K, Wada S, Cannon RD, Uehara Y, et al. Identification of two proteins induced by exposure of the pathogenic fungus Candida glabrata to fluconazole. J Chromatogr B Analyt Technol Biomed Life Sci. 2002;782:245–52.
Sanguinetti M, Posteraro B, Fiori B, Ranno S, Torelli R, Fadda G. Mechanisms of azole resistance in clinical isolates of Candida glabrata collected during a hospital survey of antifungal resistance. Antimicrob Agents Chemother. 2005;49:668–79.
Won EJ, Shin JH, Choi MJ, Lee WG, Park YJ, Uh Y, et al. Antifungal susceptibilities of bloodstream isolates of Candida species from nine hospitals in Korea: application of new antifungal breakpoints and relationship to antifungal usage. PLoS One. 2015;10: e0118770.
Xiao M, Sun ZY, Kang M, Guo DW, Liao K, Chen SC, et al.; China Hospital Invasive Fungal Surveillance Net (CHIF-NET) Study Group. Five-year national surveillance of invasive candidiasis: species distribution and azole susceptibility from the China Hospital Invasive Fungal Surveillance Net (CHIF–NET) Study. J Clin Microbiol. 2018;56:e00577–18.
Hou X, Xiao M, Chen SC, Kong F, Wang H, Chu YZ, et al. Molecular epidemiology and antifungal susceptibility of Candida glabrata in China (August 2009 to July 2014): a multi-center study. Front Microbiol. 2017;8:880.
Ko JH, Jung DS, Lee JY, Kim HA, Ryu SY, Jung SI, et al. Changing epidemiology of non-albicans candidemia in Korea. J Infect Chemother. 2019;25:388–91.
Choi H, Kim JH, Seong H, Lee W, Jeong W, Ahn JY, et al. Changes in the utilization patterns of antifungal agents, medical cost and clinical outcomes of candidemia from the health-care benefit expansion to include newer antifungal agents. Int J Infect Dis. 2019;83:49–55.
Ruan SY, Huang YT, Chu CC, Yu CJ, Hsueh PR. Candida glabrata fungaemia in a tertiary centre in Taiwan: antifungal susceptibility and outcomes. Int J Antimicrob Agents. 2009;34:236–9.
Horn DL, Neofytos D, Anaissie EJ, Fishman JA, Steinbach WJ, Olyaei AJ, et al. Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry. Clin Infect Dis. 2009;48:1695–703.
Lee I, Morales KH, Zaoutis TE, Fishman NO, Nachamkin I, Lautenbach E. Clinical and economic outcomes of decreased fluconazole susceptibility in patients with Candida glabrata bloodstream infections. Am J Infect Control. 2010;38:740–5.
Eschenauer GA, Carver PL, Patel TS, Lin SW, Klinker KP, Pai MP, et al. Survival in patients with Candida glabrata bloodstream infection is associated with fluconazole dose. Antimicrob Agents Chemother. 2018;62:e02566–17.
Ko JH, Peck KR, Jung DS, Lee JY, Kim HA, Ryu SY, et al. Impact of high MIC of fluconazole on outcomes of Candida glabrata bloodstream infection: a retrospective multicenter cohort study. Diagn Microbiol Infect Dis. 2018;92:127–32.
Tortorano AM, Dho G, Prigitano A, Breda G, Grancini A, Emmi V, et al.; ECMM-FIMUA Study Group. Invasive fungal infections in the intensive care unit: a multicentre, prospective, observational study in Italy (2006-2008). Mycoses. 2012;55:73–9.
Lortholary O, Renaudat C, Sitbon K, Madec Y, Denoeud-Ndam L, Wolff M, et al.; French Mycosis Study Group. Worrisome trends in incidence and mortality of candidemia in intensive care units (Paris area, 2002-2010). Intensive Care Med. 2014;40:1303–12.
Pfaller MA, Andes DR, Diekema DJ, Horn DL, Reboli AC, Rotstein C, et al. Epidemiology and outcomes of invasive candidiasis due to non-albicans species of Candida in 2,496 patients: data from the Prospective Antifungal Therapy (PATH) registry 2004-2008. PLoS One. 2014;9: e101510.
Singh A, Healey KR, Yadav P, Upadhyaya G, Sachdeva N, Sarma S, et al. Absence of azole or echinocandin resistance in Candida glabrata isolates in India despite background prevalence of strains with defects in the DNA mismatch repair pathway. Antimicrob Agents Chemother. 2018;62:e00195–18.
Bordallo-Cardona MÁ, Agnelli C, Gómez-Nuñez A, Sánchez-Carrillo C, Bouza E, Muñoz P, et al. MSH2 gene point mutations are not antifungal resistance markers in Candida glabrata. Antimicrob Agents Chemother. 2018;63:e01876–18.
Biswas C, Marcelino VR, Van Hal S, Halliday C, Martinez E, Wang Q, et al. Whole genome sequencing of Australian Candida glabrata isolates reveals genetic diversity and novel sequence types. Front Microbiol. 2018;9:2946.
Yao D, Chen J, Chen W, Li Z, Hu X. Mechanisms of azole resistance in clinical isolates of Candida glabrata from two hospitals in China. Infect Drug Resist. 2019;12:771–81.
Whaley SG, Berkow EL, Rybak JM, Nishimoto AT, Barker KS, Rogers PD. Azole antifungal resistance in Candida albicans and emerging non–albicans Candida species. Front Microbiol. 2017;7:2173.
Tantivitayakul P, Lapirattanakul J, Kaypetch R, Muadcheingka T. Missense mutation in CgPDR1 regulator associated with azole-resistant Candida glabrata recovered from Thai oral candidiasis patients. J Glob Antimicrob Resist. 2019;17:221–6.
Pais P, Galocha M, Viana R, Cavalheiro M, Pereira D, Teixeira MC. Microevolution of the pathogenic yeasts Candida albicans and Candida glabrata during antifungal therapy and host infection. Microb Cell. 2019;6:142–59.
Ni Q, Wang C, Tian Y, Dong D, Jiang C, Mao E, et al. CgPDR1 gain-of-function mutations lead to azole-resistance and increased adhesion in clinical Candida glabrata strains. Mycoses. 2018;61:430–40.
Brunke S, Hube B. Two unlike cousins: Candida albicans and C. glabrata infection strategies. Cell Microbiol. 2013;15:701–8.
Lortholary O, Desnos-Ollivier M, Sitbon K, Fontanet A, Bretagne S, Dromer F; French Mycosis Study Group. Recent exposure to caspofungin or fluconazole influences the epidemiology of candidemia: a prospective multicenter study involving 2,441 patients. Antimicrob Agents Chemother. 2011;55:532–8.

CME / ABIM MOC

Fluconazole-Resistant Candida glabrata Bloodstream Isolates, South Korea, 2008-2018

Authors: Eun Jeong Won, MD, PhD; Min Ji Choi, PhD; Mi-Na Kim, MD, PhD; Dongeun Yong, MD, PhD; Wee Gyo Lee, MD, PhD; Young Uh, MD, PhD; Taek Soo Kim, MD; Seung Ah Byeon, MS; Seung Yeob Lee, MD, PhD; Soo Hyun Kim, MD, PhD; Jong Hee Shin, MD, PhD
CME / ABIM MOC Released: 2/19/2021
THIS ACTIVITY HAS EXPIRED FOR CREDIT
Valid for credit through: 2/19/2022, 11:59 PM EST

Start Activity

Target Audience and Goal Statement

This activity is intended for infectious disease clinicians, public health officials, internists, intensivists, and other clinicians caring for patients with Candida glabrata fluconazole-resistant bloodstream infections.

The goal of this activity is to describe clinical outcomes, molecular mechanisms, and genotypes associated with antifungal-resistant BSI isolates of C glabrata collected from South Korean multicenter surveillance cultures during an 11-year period (2008-2018).

Upon completion of this activity, participants will:

Assess the mortality and antifungal resistance (including fluconazole resistance) of C glabrata bloodstream isolates, based on a study of South Korean multicenter surveillance cultures collected during an 11-year period (2008-2018)
Evaluate antifungal resistance molecular mechanisms, including amino acid substitutions of fluconazole-resistant C glabrata bloodstream isolates, based on a study of South Korean multicenter surveillance cultures collected during an 11-year period (2008-2018)
Determine the clinical and public health implications of outcomes and antifungal-resistant molecular mechanisms of fluconazole-resistant C glabrata bloodstream isolates, based on a study of South Korean multicenter surveillance cultures collected during an 11-year period (2008-2018)

Disclosures

As an organization accredited by the ACCME, Medscape, LLC requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.

Faculty

Eun Jeong Won, MD, PhD

Chonnam National University Medical School
Gwangju
Republic of Korea

Disclosures

Disclosure: Eun Jeong Won, MD, PhD, has disclosed no relevant financial relationships.

Min Ji Choi, PhD

Chonnam National University Medical School
Gwangju
Republic of Korea

Disclosures

Disclosure: Min Ji Choi, PhD, has disclosed no relevant financial relationships.

Mi-Na Kim, MD, PhD

University of Ulsan College of Medicine and Asan Medical Center
Seoul
Republic of Korea

Disclosures

Disclosure: Mi-Na Kim, MD, PhD, has disclosed no relevant financial relationships.

Dongeun Yong, MD, PhD

Yonsei University College of Medicine
Seoul
Republic of Korea

Disclosures

Disclosure: Dongeun Yong, MD, PhD, has disclosed no relevant financial relationships.

Wee Gyo Lee, MD, PhD

Ajou University School of Medicine
Suwon
Republic of Korea

Disclosures

Disclosure: Wee Gyo Lee, MD, PhD, has disclosed no relevant financial relationships.

Young Uh, MD, PhD

Yonsei University Wonju College of Medicine
Wonju
Republic of Korea

Disclosures

Disclosure: Young Uh, MD, PhD, has disclosed no relevant financial relationships.

Taek Soo Kim, MD

Seoul National University College of Medicine
Seoul
Republic of Korea

Disclosures

Disclosure: Taek Soo Kim, MD, has disclosed no relevant financial relationships.

Seung Ah Byeon, MS

Chonnam National University Medical School
Gwangju
Republic of Korea

Disclosures

Disclosure: Seung Ah Byeon, MS, has disclosed no relevant financial relationships.

Seung Yeob Lee, MD, PhD

Chonnam National University Medical School
Gwangju
Republic of Korea

Disclosures

Disclosure: Seung Yeob Lee, MD, PhD, has disclosed no relevant financial relationships.

Soo Hyun Kim, MD, PhD

Chonnam National University Medical School
Gwangju
Republic of Korea

Disclosures

Disclosure: Soo Hyun Kim, MD, PhD, has disclosed no relevant financial relationships.

Jong Hee Shin, MD, PhD

Chonnam National University Medical School
Gwangju
Republic of Korea

Disclosures

Disclosure: Jong Hee Shin, MD, PhD, has disclosed no relevant financial relationships.

CME Author

Laurie Barclay, MD

Freelance writer and reviewer
Medscape, LLC

Disclosures

Disclosure: Laurie Barclay, MD, has disclosed no relevant financial relationships.

Editor

Jude Rutledge, BA

Copyeditor
Emerging Infectious Diseases

Disclosures

Disclosure: Jude Rutledge, BA, has disclosed no relevant financial relationships.

CME Reviewer

Stephanie Corder, ND, RN, CHCP

Associate Director
Accreditation and Compliance
Medscape, LLC

Disclosures

Disclosure: Stephanie Corder, ND, RN, CHCP, has disclosed no relevant financial relationships.

CE Reviewer

Hazel Dennison, DNP, RN, FNP-BC, CHCP, CPHQ, CNE

Associate Director
Accreditation and Compliance
Medscape, LLC

Disclosures

Disclosure: Hazel Dennison, DNP, RN, FNP-BC, CHCP, CPHQ, CNE, has disclosed no relevant financial relationships.

Medscape, LLC staff have disclosed that they have no relevant financial relationships.

Accreditation Statements

In support of improving patient care, this activity has been planned and implemented by Medscape, LLC and Emerging Infectious Diseases. Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

For Physicians

Medscape, LLC designates this Journal-based CME activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.

Follow these steps to earn CME/CE credit*:

Read about the target audience, learning objectives, and author disclosures.
Study the educational content online or print it out.
Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

From Emerging Infectious Diseases

CME / ABIM MOC

Fluconazole-Resistant Candida glabrata Bloodstream Isolates, South Korea, 2008-2018

Authors: Eun Jeong Won, MD, PhD; Min Ji Choi, PhD; Mi-Na Kim, MD, PhD; Dongeun Yong, MD, PhD; Wee Gyo Lee, MD, PhD; Young Uh, MD, PhD; Taek Soo Kim, MD; Seung Ah Byeon, MS; Seung Yeob Lee, MD, PhD; Soo Hyun Kim, MD, PhD; Jong Hee Shin, MD, PhDFaculty and Disclosures

THIS ACTIVITY HAS EXPIRED FOR CREDIT

CME / ABIM MOC Released: 2/19/2021

Valid for credit through: 2/19/2022, 11:59 PM EST

processing....

Abstract and Introduction

Abstract

We investigated the clinical outcomes and molecular mechanisms of fluconazole-resistant (FR) Candida glabrata bloodstream infections. Among 1,158 isolates collected during multicenter studies in South Korea during 2008–2018, 5.7% were FR. For 64 patients with FR bloodstream infection isolates, the 30-day mortality rate was 60.9% and the 90-day mortality rate 78.2%; these rates were significantly higher than in patients with fluconazole-susceptible dose-dependent isolates (30-day mortality rate 36.4%, 90-day mortality rate 43.8%; p<0.05). For patients with FR isolates, appropriate antifungal therapy was the only independent protective factor associated with 30-day (hazard ratio 0.304) and 90-day (hazard ratio 0.310) mortality. Sequencing of pleiotropic drug-resistance transcription factor revealed that 1–2 additional Pdr1p amino acid substitutions (except genotype-specific Pdr1p amino acid substitutions) occurred in 98.5% of FR isolates but in only 0.9% of fluconazole-susceptible dose-dependent isolates. These results highlight the high mortality rate of patients infected with FR C. glabrata BSI isolates harboring Pdr1p mutations.

Introduction

Candida glabrata is a commensal yeast in the human gut, genitourinary tract, or oral cavity; however, it can cause serious bloodstream infections (BSIs) that result in substantial illness and death^[1]. Unlike other common Candida species, C. glabrata exhibits intrinsically low susceptibility to azole drugs, especially fluconazole, and rapidly acquires antifungal resistance in response to azole or echinocandin exposure^[1–3]. Although the incidence of echinocandin- and multidrug-resistant (MDR) C. glabrata BSIs is low, fluconazole resistant (FR) C. glabrata BSI isolates have been increasingly reported worldwide, typically at rates of 2.6%–10.6%, although these rates can reach 17%^[4–6]. Fluconazole resistance in C. glabrata is of particular concern because of the increased incidence of BSIs caused by this species in various locations worldwide^[1,4,5]. Acquired azole resistance in C. glabrata is most commonly mediated by overexpression of the drug-efflux transporter genes CgCDR1, CgCDR2, and CgSNQ2 through a gain-of-function (GOF) mutation in the transcription factor pleiotropic drug-resistance (PDR1)^[2,7,8], although other mechanisms might contribute^[9–11].

PDR1 mutations in C. glabrata associated with azole resistance have been shown to cause hypervirulence in a mouse model of systemic candidiasis, suggesting the need for careful monitoring of FR C. glabrata BSI isolates and their PDR1 mutations^[7,12]. To date, little substantial research has been conducted on PDR1 mutation incidence among FR C. glabrata BSI isolates from multicenter surveillance cultures or on mortality rates of patients infected with these PDR1 mutants. This deficit might be attributable to Pdr1p amino acid substitutions (AAS) found in FR and fluconazole-susceptible dose-dependent (F-SDD) isolates^[7,13,14], which can impede determination of whether specific Pdr1p AAS result in fluconazole resistance. Therefore, the aim of this study was to investigate the clinical outcomes, molecular mechanisms, and genotypes associated with antifungal-resistant BSI isolates of C. glabrata collected during multicenter studies in South Korea during an 11-year period (2008–2018). We focused on the mortality rates of patients infected with FR C. glabrata BSI isolates harboring the Pdr1p mutation.

Page 1 of 4

Materials and Methods

CME / ABIM MOC Information

Abstract and Introduction
Materials and Methods
Results
Discussion

References

References

Disclaimer

The educational activity presented above may involve simulated, case-based scenarios. The patients depicted in these scenarios are fictitious and no association with any actual patient, whether living or deceased, is intended or should be inferred. The material presented here does not necessarily reflect the views of Medscape, LLC, or any individuals or commercial entities that support companies that support educational programming on medscape.org. These materials may include discussion of therapeutic products that have not been approved by the US Food and Drug Administration, off-label uses of approved products, or data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal. Readers should verify all information and data before treating patients or employing any therapies described in this or any educational activity. A qualified healthcare professional should be consulted before using any therapeutic product discussed herein.

Table 1.

Table 2.

Table 3.

References

Faculty and Disclosures

Faculty

Eun Jeong Won, MD, PhD

Min Ji Choi, PhD

Mi-Na Kim, MD, PhD

Dongeun Yong, MD, PhD

Wee Gyo Lee, MD, PhD

Young Uh, MD, PhD

Taek Soo Kim, MD

Seung Ah Byeon, MS

Seung Yeob Lee, MD, PhD

Soo Hyun Kim, MD, PhD

Jong Hee Shin, MD, PhD

CME Author

Laurie Barclay, MD

Editor

Jude Rutledge, BA

CME Reviewer

Stephanie Corder, ND, RN, CHCP

CE Reviewer

Hazel Dennison, DNP, RN, FNP-BC, CHCP, CPHQ, CNE

CME / ABIM MOC

Fluconazole-Resistant Candida glabrata Bloodstream Isolates, South Korea, 2008-2018

Target Audience and Goal Statement

Disclosures

Faculty

Eun Jeong Won, MD, PhD

Min Ji Choi, PhD

Mi-Na Kim, MD, PhD

Dongeun Yong, MD, PhD

Wee Gyo Lee, MD, PhD

Young Uh, MD, PhD

Taek Soo Kim, MD

Seung Ah Byeon, MS

Seung Yeob Lee, MD, PhD

Soo Hyun Kim, MD, PhD

Jong Hee Shin, MD, PhD

CME Author

Laurie Barclay, MD

Editor

Jude Rutledge, BA

CME Reviewer

Stephanie Corder, ND, RN, CHCP

CE Reviewer

Hazel Dennison, DNP, RN, FNP-BC, CHCP, CPHQ, CNE

Accreditation Statements

For Physicians

Instructions for Participation and Credit

Fluconazole-Resistant Candida glabrata Bloodstream Isolates, South Korea, 2008-2018

Abstract and Introduction

Abstract

Introduction

Table of Contents